Gerard Letterie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gerard Letterie has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Dov Fox
University of San Diego School of Law , San Diego, California , USA
2 shared publicationsAndrew Mac Donald
Quick Step Analytics LLC, Seattle, Washington
1 shared publicationAndrew MacDonald
Quick Step Analytics LLC
1 shared publication- Nancy A. Klein
Seattle Reproductive Medicine
1 shared publication Zhan Shi
Department of Statistics, University of Washington, Seattle WA, USA
1 shared publication
Latest Publications
- 26 August 2025
- Published by Springer Nature
- p. 239-245
Racial and Ethnic Disparities in Fertility and Assisted Reproduction: Benefits and Pitfalls of AI
- 26 August 2025
- Published by Springer Nature
- p. 239-245
Racial and Ethnic Disparities in Fertility and Assisted Reproduction: Benefits and Pitfalls of AI
- 23 December 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (12) , 3317-3321
GYNs at the REI gates: unsolvable conundrum or unambiguous opportunity?
Contemporary fertility care has matured from a restricted, special interest in women’s health care where success sometimes made magazine covers to a well-honed start-to-finish process with ever-improving success rates and an ever-expanding panoply of treatment options. Innovations in both lab and clinic have been exponential and game changing. The specialty now finds itself in the enviable position of an extensive menu of highly successful treatment options but a complicated set of circumstances of access to these options. Emerging technology such as artificial intelligence could facilitate this transition and improve access. But a key corollary to access and leveraging new technology relates to having a credentialed team to deliver care on scale and maintain best practices and outcomes. The current debate focuses on this Rubik’s cube of personnel needs in reproductive endocrinology (REI) and weighs how best to expand access and maintain the culture and spirit of REI. A model to include providers other than REI viz, GYNs or APPs is now front and center. The objective of this Opinion is to define the current context for fertility care and within that context evaluate options and consider what a collaborative model that incorporates a spectrum of non-REI providers including GYNs might look like. Such a model may be feasible (or not) to expand access to care on scale while maintaining high standards and best outcomes.
- 23 December 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (12) , 3317-3321
GYNs at the REI gates: unsolvable conundrum or unambiguous opportunity?
Contemporary fertility care has matured from a restricted, special interest in women’s health care where success sometimes made magazine covers to a well-honed start-to-finish process with ever-improving success rates and an ever-expanding panoply of treatment options. Innovations in both lab and clinic have been exponential and game changing. The specialty now finds itself in the enviable position of an extensive menu of highly successful treatment options but a complicated set of circumstances of access to these options. Emerging technology such as artificial intelligence could facilitate this transition and improve access. But a key corollary to access and leveraging new technology relates to having a credentialed team to deliver care on scale and maintain best practices and outcomes. The current debate focuses on this Rubik’s cube of personnel needs in reproductive endocrinology (REI) and weighs how best to expand access and maintain the culture and spirit of REI. A model to include providers other than REI viz, GYNs or APPs is now front and center. The objective of this Opinion is to define the current context for fertility care and within that context evaluate options and consider what a collaborative model that incorporates a spectrum of non-REI providers including GYNs might look like. Such a model may be feasible (or not) to expand access to care on scale while maintaining high standards and best outcomes.
- 4 July 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (9) , 1863-1868
Moonshot. Long shot. Or sure shot. What needs to happen to realize the full potential of AI in the fertility sector?
Quality healthcare requires two critical components: patients’ best interests and best decisions to achieve that goal. The first goal is the lodestar, unchanged and unchanging over time. The second component is a more dynamic and rapidly changing paradigm in healthcare. Clinical decision-making has transitioned from an opinion-based paradigm to an evidence-based and data-driven process. A realization that technology and artificial intelligence can bring value adds a third component to the decision process. And the fertility sector is not exempt. The debate about AI is front and centre in reproductive technologies. Launching the transition from a conventional provider-driven decision paradigm to a software-enhanced system requires a roadmap to enable effective and safe implementation. A key nodal point in the ascending arc of AI in the fertility sector is how and when to bring these innovations into the ART routine to improve workflow, outcomes, and bottom-line performance. The evolution of AI in other segments of clinical care would suggest that caution is needed as widespread adoption is urged from several fronts. But the lure and magnitude for the change that these tech tools hold for fertility care remain deeply engaging. Exploring factors that could enhance thoughtful implementation and progress towards a tipping point (or perhaps not) should be at the forefront of any ‘next steps’ strategy. The objective of this Opinion is to discuss four critical areas (among many) considered essential to successful uptake of any new technology. These four areas include value proposition, innovative disruption, clinical agency, and responsible computing.
- 4 July 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (9) , 1863-1868
Moonshot. Long shot. Or sure shot. What needs to happen to realize the full potential of AI in the fertility sector?
Quality healthcare requires two critical components: patients’ best interests and best decisions to achieve that goal. The first goal is the lodestar, unchanged and unchanging over time. The second component is a more dynamic and rapidly changing paradigm in healthcare. Clinical decision-making has transitioned from an opinion-based paradigm to an evidence-based and data-driven process. A realization that technology and artificial intelligence can bring value adds a third component to the decision process. And the fertility sector is not exempt. The debate about AI is front and centre in reproductive technologies. Launching the transition from a conventional provider-driven decision paradigm to a software-enhanced system requires a roadmap to enable effective and safe implementation. A key nodal point in the ascending arc of AI in the fertility sector is how and when to bring these innovations into the ART routine to improve workflow, outcomes, and bottom-line performance. The evolution of AI in other segments of clinical care would suggest that caution is needed as widespread adoption is urged from several fronts. But the lure and magnitude for the change that these tech tools hold for fertility care remain deeply engaging. Exploring factors that could enhance thoughtful implementation and progress towards a tipping point (or perhaps not) should be at the forefront of any ‘next steps’ strategy. The objective of this Opinion is to discuss four critical areas (among many) considered essential to successful uptake of any new technology. These four areas include value proposition, innovative disruption, clinical agency, and responsible computing.
- 18 May 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (1) , 32-37
Artificial intelligence and assisted reproductive technologies: 2023. Ready for prime time? Or not
- 18 May 2023
- Published by Elsevier in Fertility and Sterility
- Vol. 120 (1) , 32-37
Artificial intelligence and assisted reproductive technologies: 2023. Ready for prime time? Or not
- 1 March 2023
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 40 (3) , 577-580
What is the status of insurance coverage for fertility services in the United States by large insurers? A patchwork system in need of repair
- 1 March 2023
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 40 (3) , 577-580
What is the status of insurance coverage for fertility services in the United States by large insurers? A patchwork system in need of repair
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 10 (1) , lsad006
Legal personhood and frozen embryos: implications for fertility patients and providers in post-Roe America
The demise of Roe v. Wade has prompted some state lawmakers to try to redefine legal personhood to begin before birth and even before pregnancy. The sweeping abortion bans passed and pending in the wake of Dobbs pose a threat to reproductive rights that extends beyond abortion. That threat spills over into in vitro fertilization (IVF) and other assisted reproductive technologies (ART). If legislatures designate embryos as legal persons, fertility clinics will be forced to change how they manage embryos, including current standard practices such as pre-implantation genetic testing, storage of unused embryos, and the disposal of those unlikely to have reproductive potential. This essay examines the many ways in which conferring the status of persons under private and public law is likely to impact patients pursuing IVF and clinics practicing ART.
- 1 January 2023
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 10 (1) , lsad006
Open AccessLegal personhood and frozen embryos: implications for fertility patients and providers in post-Roe America
The demise of Roe v. Wade has prompted some state lawmakers to try to redefine legal personhood to begin before birth and even before pregnancy. The sweeping abortion bans passed and pending in the wake of Dobbs pose a threat to reproductive rights that extends beyond abortion. That threat spills over into in vitro fertilization (IVF) and other assisted reproductive technologies (ART). If legislatures designate embryos as legal persons, fertility clinics will be forced to change how they manage embryos, including current standard practices such as pre-implantation genetic testing, storage of unused embryos, and the disposal of those unlikely to have reproductive potential. This essay examines the many ways in which conferring the status of persons under private and public law is likely to impact patients pursuing IVF and clinics practicing ART.
- 5 February 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 117 (3) , 477-480
In re: the disposition of frozen embryos: 2022
- 5 February 2022
- Published by Elsevier in Fertility and Sterility
- Vol. 117 (3) , 477-480
In re: the disposition of frozen embryos: 2022
- 1 February 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (2) , 254-260
An artificial intelligence platform to optimize workflow during ovarian stimulation and IVF: process improvement and outcome-based predictions
- 1 February 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (2) , 254-260
An artificial intelligence platform to optimize workflow during ovarian stimulation and IVF: process improvement and outcome-based predictions
- 19 April 2021
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 38 (7) , 1617-1625
Three ways of knowing: the integration of clinical expertise, evidence-based medicine, and artificial intelligence in assisted reproductive technologies
Decision-making in fertility care is on the cusp of a significant frameshift. Online tools to integrate artificial intelligence into the decision-making process across all aspects of ART are rapidly emerging. These tools have the potential to improve outcomes and transition decision-making from one based on traditional provider centric assessments toward a hybrid triad of expertise, evidence, and algorithmic data analytics using AI. We can look forward to a time when AI will be the third part of a provider’s tool box to complement expertise and medical literature to enable ever more accurate predictions and outcomes in ART. In their fully integrated format, these tools will be part of a digital fertility ecosystem of analytics embedded within an EMR. To date, the impact of AI on ART outcomes is inconclusive. No prospective studies have shown clear cut benefit or cost reductions over current practices, but we are very early in the process of developing and evaluating these tools. We owe it to ourselves to begin to examine these AI-driven analytics and develop a very clear idea about where we can and should go before we roll these tools into clinical care. Thoughtful scrutiny is essential lest we find ourselves in a position of trying to modulate and modify after entry of these tools into our clinics and patient care. The purpose of this commentary is to highlight the evolution and impact AI has had in other fields relevant to the fertility sector and describe a vision for applications within ART that could improve outcomes, reduce costs, and positively impact clinical care.
- 19 April 2021
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 38 (7) , 1617-1625
Three ways of knowing: the integration of clinical expertise, evidence-based medicine, and artificial intelligence in assisted reproductive technologies
Decision-making in fertility care is on the cusp of a significant frameshift. Online tools to integrate artificial intelligence into the decision-making process across all aspects of ART are rapidly emerging. These tools have the potential to improve outcomes and transition decision-making from one based on traditional provider centric assessments toward a hybrid triad of expertise, evidence, and algorithmic data analytics using AI. We can look forward to a time when AI will be the third part of a provider’s tool box to complement expertise and medical literature to enable ever more accurate predictions and outcomes in ART. In their fully integrated format, these tools will be part of a digital fertility ecosystem of analytics embedded within an EMR. To date, the impact of AI on ART outcomes is inconclusive. No prospective studies have shown clear cut benefit or cost reductions over current practices, but we are very early in the process of developing and evaluating these tools. We owe it to ourselves to begin to examine these AI-driven analytics and develop a very clear idea about where we can and should go before we roll these tools into clinical care. Thoughtful scrutiny is essential lest we find ourselves in a position of trying to modulate and modify after entry of these tools into our clinics and patient care. The purpose of this commentary is to highlight the evolution and impact AI has had in other fields relevant to the fertility sector and describe a vision for applications within ART that could improve outcomes, reduce costs, and positively impact clinical care.
- 1 November 2020
- Published by Elsevier in Fertility and Sterility
- Vol. 114 (5) , 1026-1031
Artificial intelligence in in vitro fertilization: a computer decision support system for day-to-day management of ovarian stimulation during in vitro fertilization
- 1 November 2020
- Published by Elsevier in Fertility and Sterility
- Vol. 114 (5) , 1026-1031
Artificial intelligence in in vitro fertilization: a computer decision support system for day-to-day management of ovarian stimulation during in vitro fertilization